Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

596 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study.
Katoh T, Igawa Y, Yamaguchi O, Kato D, Hamada T, Kuroishi K. Katoh T, et al. Among authors: yamaguchi o. Low Urin Tract Symptoms. 2020 Jan;12(1):68-80. doi: 10.1111/luts.12286. Epub 2019 Sep 30. Low Urin Tract Symptoms. 2020. PMID: 31571403 Free PMC article. Clinical Trial.
Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study.
Katoh T, Kakizaki H, Lee KS, Ishida K, Katou D, Yamamoto O, Jong JJ, Sumarsono B, Uno S, Yamaguchi O. Katoh T, et al. Among authors: yamaguchi o. Low Urin Tract Symptoms. 2021 Jan;13(1):98-107. doi: 10.1111/luts.12339. Epub 2020 Sep 25. Low Urin Tract Symptoms. 2021. PMID: 32975024 Free PMC article. Clinical Trial.
Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, Gotoh M, Yoshida M, Yokoyama O, Seki N, Okitsu A, Hamada T, Kobayashi A, Kuroishi K. Yamaguchi O, et al. Int J Urol. 2019 Mar;26(3):342-352. doi: 10.1111/iju.13868. Epub 2018 Dec 13. Int J Urol. 2019. PMID: 30548692 Free PMC article. Clinical Trial.
Efficacy and safety of 25 and 50 μg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program.
Yamaguchi O, Juul KV, Falahati A, Yoshimura T, Imura F, Kitamura M. Yamaguchi O, et al. Low Urin Tract Symptoms. 2020 Jan;12(1):8-19. doi: 10.1111/luts.12276. Epub 2019 Aug 9. Low Urin Tract Symptoms. 2020. PMID: 31397969 Free PMC article. Clinical Trial.
Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).
Kakizaki H, Lee KS, Yamamoto O, Jong JJ, Katou D, Sumarsono B, Uno S, Yamaguchi O. Kakizaki H, et al. Among authors: yamaguchi o. Eur Urol Focus. 2020 Jul 15;6(4):729-737. doi: 10.1016/j.euf.2019.10.019. Epub 2019 Nov 11. Eur Urol Focus. 2020. PMID: 31718957 Free article. Clinical Trial.
596 results